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Abstract 
Aminopeptidase N(APN) has been shown as a receptor of several coronaviruses, 
such as HCoV-229E, TGEV, CCoV and FeCoV. Bestatin and Actinonin are inhibitors 
which can block APN enzymatic activity. These inhibitors bind to the catalytic site of 
APN, while viruses bind to the outer surface of APN. Here we investigate the 
mechanism of APN inhibition on protein-protein binding, receptor expression and 
coronavirus entry. We find that these chemical compounds can inhibit the protein-
protein interaction between APN and Coronavirus spike; these inhibitors can also 
regulate APN RNA and protein expression; additionally, these compounds can inhibit 
the pseudovirus entry of HCoV-229E into human cells at a certain level. Additionally, 
coronavirus spike-treated human cells show a decrease in APN expression. This 
phenomenon may reveal an adaptation of cells to the different treatments and conditions. 
Our research may provide a new potential strategy for antiviral treatment.  
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Introduction 
Coronaviruses (CoV) are a group of enveloped, single-stranded, positive-sense RNA 
viruses which belong to Coronavinae, a subfamily of Coronaviridae in the order 
Nidovirales. They are the largest RNA viruses discovered to date, with genome sizes 
range approximately from 26 to 32 kilo-bases (kb). 
Currently, coronaviruses are classified into four genera: Alpha (α), Beta (β), Gamma 
(γ) and Delta (δ) (1). Mammalian coronaviruses mainly belong to the genera of Alpha 
and Beta; avian coronaviruses all belong to the genera of Gamma and Delta. Several 
coronaviruses are pathogenic in humans and domestic animals, such as Human 
Coronavirus 229E (HCoV-229E) (2), Human Coronavirus NL63 (HCoV-NL63) (3, 4), 
Transmissible Gastroenteritis Virus (TGEV), Feline Coronavirus (FeCoV), Porcine 
Epidemic Diarrhea Virus (PEDV) and Canine Coronavirus (CCoV) in AlphaCoV; 
Coronavirus HKU1 (CoV-HKU1) (5), Human Coronavirus OC43 (HCoV-OC43) (6),  
Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) (7, 8), Middle East 
Respiratory Syndrome Coronavirus (MERS-CoV) (9, 10), Mouse Hepatitis Virus (MHV) 
and Bovine Coronavirus (BCoV) in BetaCoV; Avian infectious bronchitis virus (IBV) in 
GammaCoV and porcine coronavirus HKU15 in DeltaCoV (11, 12). The coronavirus 
virion contains four major structural proteins: the spike (S), membrane (M), envelope (E) 
and nucleocapsid (N) protein. Trimer of S proteins forms the spike of CoV, which gives 
the virion the crown-like appearance under microscopy. The ectodomain of S protein 
consists of two subdomains, receptor binding S1 subunit and membrane-fusion S2 
subunit (13). S1 is critical in receptor recognition and virus binding, providing receptor 
affinity, while S2 mediates the virus fusion and entry. Traditionally, two domains have 
been identified in S1: N-terminal domain (S1-NTD) and C-terminal domain (S1-CTD), 
distinguished by their location and functional differences. At least one of these two 
domains functions as the Receptor Binding Domain (RBD). S1-NTD usually recognizes 
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sugar receptor, and S1-CTD usually binds protein receptors (11, 14-16). Recent cyro-EM 
studies on S protein structure show that the S1 subunit contains 5 independent structural 
sub-domains, namely, "0", "A", "B","C", and "D". Although the absence of "0" domain is 
found in some CoVs, the "0" and "A" domain combined are thought to be associated with 
the sugar recognition. The domain "B"  provides protein receptor affinity (17-21). 
Coronaviruses recognize a variety of protein and sugar receptors. Most of the Alpha-
CoVs utilize the APN as their receptor, especially feline APN (22). An exempt is HCoV-
NL63, which utilizes the Angiotensin-converting enzyme 2 (ACE2), a protein receptor of 
SARS-CoV in BetaCoV. APN has been demonstrated to facilitate PEDV infection (16, 
23-26), while there is still a debate whether APN functions as its receptor (27, 28). Other 
BetaCoVs, like MERS-CoV, which uses Dipeptidyl peptidase 4 (DPP4) as the receptor; 
MHV, recognizes CEACAM1. Sugar has been demonstrated to be the receptor of OC43, 
HCoV-HKU1, BCoV and IBV. Additionally, TGEV, PEDV and MHV also utilize sugar 
as co-receptor. Receptors of some coronaviruses are listed below (Table 1). 
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Table 1. Receptor recognition of some coronaviruses 
 
Genera CoV Protein Receptor Sugar Receptor/ Co-receptor 
α TGEV APN(29) Sialic acid (14, 15) 
PEDV APN* Sialic acid (16) 
FeCoV APN(30) / 
CCV APN(30) / 
HCoV-229E APN(31) / 
HCoV-NL63 ACE2(32) / 
β SARS-CoV ACE2(33) DC-SIGN, DC-SIGNR(34) 
HCoV-OC43 / Sialic acid (35) 
HCoV-HKU1 / Sialic acid (36) 
MERS-CoV DPP4(37) / 
MHV CEACAM1a(38, 39) / 
γ IBV / Sialic acid (40) 
 
*: There is still a debate whether APN is the receptor of PEDV. 
/ : means unknown or unavailable. 
 
TGEV is one of the most significant coronaviruses in swine. The virus, which can 
induce vomit and watery diarrhea among almost all classes of pigs, spreads rapidly and 
causes nearly 100% mortality in newborn piglets. TGEV mainly infects the small 
intestine of the host, which can lead to shortening of villi by reducing the number of 
absorptive cells. As a result, the infected pigs develop digestive disorder and finally die 
from dehydration. TGEV also provides the backbone of a novel Chimeric Swine Enteric 
Coronavirus (SeCoV) (41). In addition, porcine respiratory coronavirus (PRCV) (42) is 
known to be a mutant of TGEV. 
229E is the first sequenced human CoV isolated in 1960s from patients with 
common cold (2). The virus infects a wide range of human regardless of gender, age or 
geographic areas. In most cases, HCoV-229E infection only raises mild cold-like 
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symptoms, such as nasal discharge, cough and headache (43). However, severe 
respiratory infections by HCoV-229E can also cause hospitalization in children, the 
elderly and immunocompromised patients (44). Titers of HCoV-229E antibodies usually 
decrease after one year infection, which indicates numerous infections of HCoV-229E 
during lifetime (45). Therefore, lacking treatment for HCoV-229E could induce 
substantial economic cost and decreased life quality.   
Mammalian Aminopeptidase N (APN or CD13), a member of M1 family, is a zinc-
dependent ectoenzyme, which is widely expressed on the surface of renal and intestinal 
epithelia cells, and in nervous system. APN modulates neutral peptides cleavage from N-
terminus of various oligopeptides, also functions as the receptor of many coronaviruses 
and conducts cellular signaling (46). APN is a critical marker and target in cancer 
metastasis and angiogenesis (47, 48).  
APN forms head-to-head homodimers, each monomer has four distinct domains.  
The N-terminus of the substrate binds to the zinc active site of APN (Figure 1A), the 
remaining residues of the substrate can be accommodated into APN’s spacious cavity, 
which is surrounded by the four domains of APN and can also be extended to 
accommodate peptides with more amino acids (49). As a member of M1-family, APN 
also has two conformations: the open catalytically inactive form and the closed 
catalytically active form. Coronaviruses bind to the region distant from the catalytic site. 
The "virus-binding motifs" (VBMs) on the surface of APN have been mapped (49) 
(Figure 1B): VBM1 (residues 283-292) for HCoV-229E, VBM2 (residues 728-744) for 
TGEV and VBM3 (residues 760-784) for FeCoV/CCoV (25, 49, 50).  
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Figure 1. Structure of APN ectodomain and the binding sites (PDB ID: 4FKK) (49). (A) Four 
subdomains of APN ectromain are the head, side, body and tail domains. Substrates bind Zinc in 
the cavity surrounded by the four domains of APN.  (B) Coronavirus-binding sites of HCoV-
229E and TGEV. 
 
Previously, it is commonly believed that coronavirus binding site is unrelated with 
the catalytic activity of APN, since APN mutants in active site or adding inhibitors (such 
as bestatin) do not interfere with coronavirus infection (26, 27, 51). However, a recent 
study shows that inhibitors anchoring active site will suppress virus binding by changing 
APN conformation (52). 
Bestatin (Ubenimex), first isolated from the culture filtrate of Streptomyces 
olivoreticuli in 1976 (53), is the most widely used APN inhibitor. It is a competitive, 
reversible, slow-binding metalloprotease inhibitor which binds to catalytic site of APN. 
Actinonin, an antibacterial agent, was first isolated from a Malayan strain of 
Actynomicetes, and later also found to be an inhibitor of APN in 1985. In our research, 
we use TGEV and 229E spikes to investigate their relationship with APN in the presence 
or absence of active site inhibitors, and reversely, we also investigate the effect of these 
inhibitors on APN expression and virus entry. 
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Results and Discussion 
Protein preparation 
We aligned sequence of TGEV and HCoV-229E spikes with HCoV-NL63 (Genbank 
accession number YP_003767) (18) using Clustal Omega to identify the genes of interest 
(GOI) (Figure 2). GOI was amplified by overhang PCR using specific forward and 
reverse primers, in the PCR reaction, the restriction sites were added, and honeybee 
melittin signal peptide was fused to the N-terminus of GOI to increase the secretion 
efficiency. PFastBac 1 pre-inserted with IgG4 Fc sequence was used as the cloning vector 
(Figure 3). Briefly, both the template of interest and vector were digested by restriction 
enzymes and then ligated using DNA ligase. Recombinant plasmid was selected from 
ampicillin resistant colonies, and verified by diagnostic digestion and sequencing.  
 
 
 
 
Figure 2. Recombinant plasmids preparation. A. Sequence alignment of TGEV and HCoV-
229E with HCoV-NL63. We selected TGEV domain B and HCoV-229E S1 subunit as Genes of 
Interest (GOI); B. Map of recombinant plasmid. Honeybee melittin signal sequence was added to 
the N-terminus of the GOI by PCR, and Human IgG4 Fc sequence was inserted into the vector 
previously.  
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Proteins were expressed using Bac-to-Bac Baculovirus Expression Systems, and 
then purified using affinity column and gel filtration. The purified proteins were 
examined by SDS-PAGE, and the molecular weight of each protein was consistent with 
prediction (Figure 3). 
To investigate whether inhibitors acting on APN catalytic site interfere with 
coronavirus binding, we purified truncated TGEV spike (residues 522-672) and 229E 
spike (residues 17-525) fused with Human IgG4 Fc tag, porcine APN (pAPN) 
ectodomain (residues 62-963) and human APN (hAPN) ectodomain (residues 33-967) 
fused with a C-terminal 6 Histidine sequence (His). We also used human ACE2 
ectodomain (hACE2) (residues 19-615), human DPP4 (hDPP4) ectodomain (residues 39-
766), SARS truncated spike (residues 306-527) and MERS truncated spike (residues 367-
588) previously purified by lab colleagues (Figure 3).  
 
 
Figure 3. Proteins on SDS-PAGE. SDS-PAGE analysis of recombinant pAPN-His (Genbank 
accession number CAA82641.1), hAPN-His (Genbank accession number BC058928.1), hACE2-
Fc (Genbank accession number AY623811), hDPP4-His (Genbank accession number 
NP_001926.2), 229E-S1-Fc (Genbank accession number NP_073551), TGEV-CTD-Fc (Genbank 
accession number CAA29175), SARS-RBD-His (Genbank accession number NC_004718) and 
MERS-RBD-Fc (Genbank accession number AFS88936.1).  
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Effects of catalytic inhibitors on binding interactions 
To study the binding interaction between spike and APN, we used Dot blot Hybridization 
Assay (Table 2). Purified TGEV-RBD, HCoV-229E-S1, hAPN and pAPN ectodomain 
were used in all the binding affinity assays. The receptor of HCoV-229E is hAPN, while 
according to our experiment, HCoV-229E spike protein had higher affinity to pAPN than 
hAPN. Considering that pAPN and hAPN have 80% amino acid sequence identity, and 
pAPN matches well with hAPN in the ectodomain (Figure 4). We used pAPN instead of 
hAPN in HCoV-229E binding assays.  
 
 
 
Figure 4. Match of pAPN and hAPN ectodomains. Match of pAPN ectodomain (in yellow) 
(PDB ID: 5LDS ) with hAPN ectodomain (in blue) (PDB ID: 5LHD) by UCSF Chimera (52).  
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Table 2. Binding affinity of TGEV and HCoV-229E spike to APNs based on Dot 
Blot Hybridization Assay 
 
Coronavirus spike hAPN pAPN 
TGEV - ++ 
HCoV-229E + ++ 
  
 - No binding affinity 
 + Weak binding affinity 
 ++ Strong binding affinity 
 
Bestatin and actinonin are among the most widely used APN inhibitors, anchoring 
zinc-binding active site. Bestatin is a potent reversible inhibitor with IC50 of 16 μM (54-
56). Actinonin is also a competitive inhibitor of APN with IC50 of 1.99 μM (57) . Same 
amount of TGEV or 229E proteins was added to the nitrocellulose membrane, and then 
incubated with pAPN with or without inhibitor (actinonin or bestatin) in working 
concentration (100 μM), respectively (Figure 5). We used MERS-CoV truncated spike as 
negative control (not shown). According to the results, in the presence of actinonin and 
bestatin, binding of both TGEV and HCoV-229E spike were attenuated. In addition, the 
bindings in actinonin treated proteins were weaker than bestatin treated ones, which was 
also corresponding to their affinity to APN. 
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Figure 5. Dot Blot Hybridization Assay of TGEV and 229E spike with pAPN. pAPN was 
preincubated with PBS, actinonin or bestatin overnight. Bindings were detected using antibodies 
against C-terminal Fc tag; 
 
We further used ELISA to study the binding interference of APN catalytic inhibitors 
(Figure 6). We saw that the inhibition of actinonin (Figure 6A) and bestatin (Figure 6B) 
was dose dependent. We also measured the binding affinity of SARS-CoV and MERS-
CoV spike with hACE2 and hDPP4 in the presence of inhibitor, respectively. Sitagliptin 
is a catalytic inhibitor of DPP4. ELISA showed that sitagliptin did not decrease the 
binding of spike proteins to the receptor (Figure 6C), which was consistent with the 
previous reports showing that MERS-CoV entry could not be blocked by DPP4 inhibitors 
(58, 59). MLN-4760 is a potent ACE2 inhibitor anchoring the active site of ACE2 (60). 
In our result, SARS-CoV spike binding was unrelated with ACE2 inhibitor MLN-4760 
(Figure 6D).  
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Figure 6. Interactions between spike and receptors in the presence of inhibitors. (A) (B) 
ELISA showing the binding interactions between TGEV spike and APN with or without 
inhibitors. The binding affinity of TGEV spike with pAPN in the absence of  inhibitors was used 
as the standard and taken as 100%. Error bars indicate S.E. (compared with the standard two-
tailed t test; *, p<0.05; **, p<0.01; ***, p<0.001, n=3). (C) (D) Binding of MERS-CoV spike 
with DPP4, and SARS-CoV spike with ACE2 in the presence or absence of inhibitors. The 
binding affinity of CoVs spike with receptors in the absence of  inhibitors was used as the 
standard and taken as 100%. Error bars indicate S.E. (compared with the standard two-tailed t test; 
*, p<0.05; **, p<0.01; ***, p<0.001, n=6).  
 
BLItz was used for the concurrent association of TGEV and 229E spike with APN. 
Affinity constants were shown in Table 3. Affinity constants of both TGEV and 229E 
spike remained unchanged regardless of the concentration of each protein. However, the 
association rate and maximum binding decreased with lower APN concentration when 
we fixed the concentration of spike (the spike was unsaturated) (Figure 7A). Then, we 
fixed both the concentration of spikes and APN. For both TGEV (Figure 7B) and HCoV-
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229E (Figure 7C), the affinity constant (KD), association rate constant (ka) and 
dissociation rate constant (kd) were unchanged (Table 3), while the maximum association 
rate (Vmax) and maximum binding decreased in the presence of bestatin. The decrease in 
binding rate reflected the decrease of free APN available for spike binding. In a word, 
bestatin could inhibit binding of spike and APN in a similar way as non-competitive 
inhibitors. For the association of MERS-CoV and hDPP4, bestatin did not change any 
affinity constants or binding rates (Figure 7D). In other words, bestatin did not have an 
effect on the binding between MERS-CoV spike and DPP4.  
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Table 3. Affinity constants for binding interactions 
 
Coronaviruses  
spike 
Receptors  
(μM) 
Inhibitors 
 (μM) 
KD 
(M) 
ka  
(1/Ms) 
kd 
(1/s) 
R2 
TGEV 
(50μg/ml) 
0.0625 a 0  1.81e-8 3.00e5 5.44e-3 0.984 
0.25 a 0  1.90e-8 2.12e5 4.19e-3 0.988 
1a 0  2.60e-8 1.21e5 3.16e-3 0.961 
0.25 a  25* 5.34e-8 0.95e5 5.04e-3 0.993 
0.25 a  250*  1.93e-8 1.53e5 2.96e-3 0.973 
HCoV-229E 
(50μg/ml) 
1 a  0  5.72e-8 6.26e4 3.58e-3 0.960 
1 a  25* 7.98e-8 4.42e4 3.53e-3 0.966 
1 a  250*  10.6e-8 5.64e4 9.16e-3 0.958 
MERS-CoV  
(50μg/ml) 
1 b 0  4.86e-7 3.00e5 5.44e-3 0.998 
1 b 250*  8.34e-7 6.27e3 5.23e-3 0.995 
1 b 250# 8.80e-7 2.12e5 4.19e-3 0.999 
 
 a: pAPN;   
 b: hDPP4; 
 *: Bestatin;   
 #: Sitagliptin 
 KD (M) - Measured affinity of interaction; affinity constant in Molar; 
 ka (1/Ms) - Association rate constant; 
 kd (1/s) - Dissociation rate constant; 
 R2 value reports goodness of fit. 
  
 
Likewise, we measured the affinity constants of MERS-CoV spike with hDPP4 
using BLItz (Figure 7E). In the presence of sitagliptin, the affinity constants, as well as 
Vmax and maximum binding did not change (Table 3). The active site inhibitor sitagliptin 
did not inhibit spike-receptor binding.  
 
  14 
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Figure 7. Concurrent binding between CoV spikes and receptors by BLItz. Sensors loaded 
with coronavirus spike. The data were shown using global curve fitting automatically by the 
system from the start of association. (A) Binding of TGEV spike with pAPN. The concentrations 
of TGEV were 50 μg/ml, pAPN were 1 μM, 0.25 μM and 0.0625 μM. (B)(C) Binding of TGEV 
spike or HCoV-229E spike with pAPN in the presence of Bestatin. The concentrations of bestatin 
were 0μM, 25μM and 250 μM.  The concentrations of TGEV and HCoV-229E spike were 50 
μg/ml. (D) Binding of MERS-CoV spike with DPP4 in the presence of Bestatin. The 
concentration of MERS-CoV spike was 50 μg/ml. The concentrations of bestatin were 0 μM and 
250 μM. 250 μM of Bestatin in PBS was used as a negative control. (E) Binding of MERS-CoV 
spike with DPP4 in the presence of sitagliptin. The concentrations of  sitagliptin were 0 μM and 
250 μM. 250 μM of sitagliptin in PBS was used as a negative control. 
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Effects of APN inhibitors and spikes on APN expression  
Apart from spike binding, the density of APN in cells may also contribute to viral entry. 
To investigate whether APN inhibitor have an effect on APN expression in cells, we 
treated human cells with bestatin and checked APN expression by Western blot 
and quantitative polymerase chain reaction (qPCR). First, we treated Huh 7 cells with 
bestatin at different concentrations (Figure 8A). At the concentration of 100 μM, a 
significant decrease of APN expression level was shown. We then chose 100 μM as the 
working concentration in the following experiments.  
To study the effect of inhibitors on APN expression with time, we treated Huh 7 
cells with bestatin (100 μM) in 10% FBS supplemented DMEM, and analyzed APN 
expression from 0 to 24 hours after treatment. For the first 2 hours post-treatment, a slight 
increase of APN expression was found after bestatin or actinonin treatment, followed by 
a decrease overtime (Figure 8B). Similarly, qPCR (Figure 8D) showed an increase in 
RNA 2 hours after treatment. The RNA rising in the early stages of inhibitors treatment 
was consistent with the increase of APN. Later, APN expression dropped. The fluctuation 
in RNA transcription may not be the dominant factor of the decreased APN in protein 
level. Other factors may play a role in the APN reduction.   
  17 
 
 
Figure 8. Effects of bestatin and Actinonin on APN expression in Huh7 cells. (A) Western 
blot showing the effects of bestatin on APN expression at different concentrations. Huh7 cells 
were treated with bestatin for 24 hours. APN was detected in cell lysates. (B) Western blot 
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showing the effects of actinonin on APN expression at (100 μM) at different time points post-
treatment. APN was detected in cell lysates. APN was detected in cell lysates. (C) Western blot 
showing APN expression in Huh7 cells after bestatin treatment(100 μM) at different time points. 
APN was detected in cell lysates.βactin was used as the internal reference. (D) Effect of 
actinonin and bestatin on APN transcription levels by qRT-PCR. GAPDH was used as the 
internal reference.  
 
It has been reported that SARS-CoV is related with ACE2 downregulation upon 
infection on lung cell surface (61). To investigate whether HCoV-229E or TGEV spike 
has a similar effect on APN, we treated cells with spikes (Figure 9), and detected the 
change of APN expression levels at different time points. Huh7 cells was treated with 
HCoV-229E spike, and HEK 293T-pAPN cells treated with TGEV spike. Under the 
treatment of spikes, APN expression decreased over time.  
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Figure 9. Effects of HCoV-229E and TGEV spike on APN in cells. (A) Effects of HCoV-229E 
spike  (20 μg/ml) on APN in Huh7 cells at different time points.  (B) Effects of TGEV spike  (20 
μg/ml) on APN in 293T/ pAPN cells at different time points. APN was detected in cell lysates by 
western blot. β-actin was used as the internal reference. 
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Effects of APN inhibitors on pseudovirus entry 
To further confirm the influence of bestatin on viral entry, we did pseudotype assay of 
HCoV-229E. HEK 293T cells expressing human, porcine, feline and bat APN were used 
to confirm the receptor of HCoV-229E. According to the results, HCoV-229E 
pseudovirus could infect 293T cells with hAPN, pAPN and fAPN (Figure 10A). Huh7 
cells were used for pseudovirus entry of HCoV-229E. After bestatin treatment for 24 
hours, nearly 30% of the infection was prohibited (Figure 10B).  
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Figure 10. Effect of bestatin on HCoV-229E pseudovirus entry. (A) Pseudotyped HCoV-229E 
entry into cells expressing different receptors. The pseudovirus entry of HCoV-229E to 
293T/hAPN was used as the standard and taken as 100%. (B) Effect of  bestatin on HCoV-229E 
pseudovirus entry into Huh7 cells. Error bars indicate S.E. (compared with the standard two-
tailed t test; *, p<0.05; **, p<0.001; n=4).  
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Discussion  
Receptor binding is the first and most significant step in coronavirus infection. Structure 
studies during the last decade had revealed some interactions between coronavirus spikes 
and receptors (49, 50, 62). It is commonly believed that catalytic activity of APN is not 
associated with coronavirus binding (51), therefore, catalytic inhibitors of APN would 
not interfere with coronavirus entry. However, recent studies have indicated that these 
inhibitors may have some impact on the interaction between APN and coronavirus spike, 
such as TGEV and pAPN (52). However, limitted researches have ever been conducted 
using APN and coronavirus spike proteins. Our research has determined the binding 
affinity of 229E or TGEV spike with pAPN, and further elucidated the inhibition effect 
of catalytic inhibitors of APN like bestatin or actinonin on spike-receptor binding. 
According to some literature, the binding sites of coronavirus spike and APN catalytic 
inhibitors are different. However, our studies indicate that these inhibitors may play a 
role in the interaction between APN and coronavirus spike, the inhibitors might interfere 
with the coronavirus binding sites of APN. Our results are consistent with a previously 
report that these inhibitors probably hinder APN transition to the virus-specific open form 
(52), and consequently, the APN is no longer available to bind coronavirus spike. In 
addition, overdosed inhibitors could not completely block the spike binding, which might 
account for the reversibility of the inhibitors. APN binds Bestatin in a rapidly reversible 
process (63). As a result, free APN for spike binding is always available. A competition 
between spike and inhibitor in APN binding may also exist.  
ACE2 and DPP4 are also metalloenzymes and receptors for coronavirus (64, 65), 
while according to our results, inhibitors binding to the active sites of these proteins do 
not block the binding of coronavirus.  
The effect of APN catalytic inhibitors might be affected by many factors, such as 
binding affinity and receptor density. It is unknown which one is the determinant factor 
for the effect of the inhibition of pseudovirus entry. As mentioned above, APN active site 
inhibitors also function as reversible inhibitors of spike binding to APN. Moreover, APN 
inhibitors also have some effect on the expression of APN. The early-stage RNA rising 
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may be responsible for the increase of APN protein under the treatment of inhibitors. It is 
unknown the detailed mechanism of the enhancement of gene expression in the early 
time when treated with these inhibitors. In the late stage of bestatin or actinonin treatment, 
the APN protein decreased, however, the transcription of APN did not. Therefore, other 
factors might account for the reduction of APN in the late stages of the treatment of these 
inhibitors. More studies should be done to reveal the underlying mechanism of the APN 
reduction in the treatment of its inhibitors. Considering the function of APN, the 
reduction of APN might account for the endocytosis, phagocytosis or degradation (46). 
Similar to SARS-CoV, the spike of HCoV-229E and TGEV could also reduce APN 
expression in cells (61). The cells might utilize the strategy to decrease their receptor 
density to protect them from virus infection. The cell surface expression of the 
chemokine receptors is regulated through their interaction with membrane trafficking 
pathways in their role as virus receptors. Similarly, spike protein may induce APN 
internalization and down modulation through unknown ways, which needs further studies 
(66). The cells may have evolved these mechanisms as an adaptation to the different 
conditions. 
In conclusion, our study demonstrates the effect of APN enzymatic inhibitors on 
spike-receptor binding, APN expression and pseudovirus entry. These findings will 
provide a new potential strategy towards antiviral therapy.   
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Materials and Methods 
PBS:   NaCl 8.00 g, KCl 0.20 g, Na2HPO4 1.44 g, KH2PO4 0.24 g, 
    pH 7.4 (1000 mL). 
PBST:   PBS+0.05% Tween-20 
NaN3 Stock:  20% NaN3 (1000 mL). 
Buffer A1:  NaCl 29.22 g, KCl 0.20 g, Na2HPO4 1.44 g, KH2PO4   
   0.24 g, Imidazole 0.34 g, NaN3 Stock 1 mL, pH 7.4 (1000 mL). 
Buffer B1:  NaCl 29.22 g, KCl 0.20 g, Na2HPO4 1.44 g, KH2PO4 0.24 g,  
   Imidazole 34.0 g, NaN3 Stock 1 mL, pH 7.4 (1000 mL). 
Buffer A2:  Tris-base 2.42 g, NaCl 29.22 g, NaN3 Stock 1 mL, 
    pH 7.4 (1000 mL). 
Transfer buffer:  Tris-base 3.02 g, Glycine 14.26 g, 20% Methanol (V:V) 
Running buffer: Tris-base 3.02 g, Glycine 18.80 g, SDS 10.00 g (1000 mL). 
Distaining buffer: Distilled water 450 mL, Methanol 450 L, Acetic acid 100 mL.  
Coating buffer:  Na2CO3 1.59 g; NaHCO3 2.94 g, pH 9.6. (1000 ml); 
Blocking buffer:  PBS+5% Milk; 
Diluted buffer:  PBST+1% Milk; 
Stopping solution:  2M H2SO4; 
Cell lysis buffer:  NaCl 11.68 g, Triton X-100 1.0% (V:V), Tris Base 6.05 g, pH 8.0. 
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Protein Preparation 
Polymerase Chain Reaction(PCR): Genes of interest (GOI) were amplified by 
overhang PCR using specific forward and reverse primers (listed in Table below). 
Honeybee melittin signal peptide was fused to the N-terminus of GOI to increase the 
secretion efficiency. The primers were designed adding restriction site, and tagged with 6 
Histidines (only receptors) in the C-terminus of GOI. Overhang PCR was operated on 
Eppendorf® Mastercycler. The PCR conditions were initial denaturation 5minutes at 
95°C, cycle denaturation for 30 seconds at 95°C, and annealing for 30 seconds (between 
48-72°C), extension for 5 minutes at 72°C, and final extension was at 72°C for 10min (30 
cycles). DNA fragments with GOI were separated by agarose gel electrophoresis (140V 
for 20 minutes) and extracted by QIAquick Gel Extraction Kit (QIAGEN, Hilden, 
Germany). 
 
Table 4. Reaction mixture of PCR 
 
Component Volume 
10×pfu buffer 10 μl 
PfuTM ultra II fusion HS DNA Polymerase (2.5 U/μl) 2 μl 
Template DNA (100 ng/μl) 2 μl 
Forward primer (10 ng/μl) 10 μl 
Reverse primer (10 ng/μl) 10 μl 
dNTP mix (2.5 mM each NTP) 8 μl 
H2O 58 μl 
Total reaction volume 100 μl 
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Table 5. Primers for TGEV and HCoV-229E spike 
 
GOI Forward Primer Reverse Primer 
TGEV spike ATAGGATCCATGAAATTCTT 
AGTCAACGTTGCCCTTGTTT 
TTATGGTCGTGTACATTTCTT 
ACATCTATGCTTCATTTTACA 
CTCATACAATCGTGA 
ATAGGTACCTCCACT 
TCCACCATTGTCAGA 
GGGCACGC 
 
HCoV-229E spike ATAGGATCCATGAAATTCTT 
AGTCAACGTTGCCCTTGTT 
TTTATGGTCGTGTACATTTC 
TTACATCTATGCTCAGACCA 
CCAACGGCCTGAA 
ATAGGTACCGGAGAA 
GCCGTAGGAGGTGA 
 
 
Recombination DNA plasmid of porcine Aminopeptidase N ectodomain (pAPN), human 
Aminopetidase N ectodomain (hAPN), human Angiotensin-Converting Enzyme 2 
ectodomain (hACE2), human Dipeptidyl peptidase-4 ectodomain (hDPP4), MERS-CoV 
spike (MERS spike), and SARS-CoV spike (SARS spike) were constructed previously. 
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Table 6. Sequence information of purified proteins 
 
Protein Genbank accession number Residues Tag 
TGEV spike CAA29175 522-672 Human IgG4 Fc 
HCoV-229E spike NP_073551 17-525 Human IgG4 Fc 
SARS-CoV spike NC_004718 306-527 His6 
MERS-CoV spike AFS88936.1 367-588 Human IgG4 Fc 
pAPN  CAA82641.1 62-963 His6 
hAPN  BC058928.1 33-967 His6 
hACE2  AY623811 19-615 Human IgG4 Fc 
hDPP4  NP_001926.2 39-766 His6 
 
Digestion and Ligation: Both PCR products and vectors were digested by High Fidelity 
(HF TM) Restriction enzymes in CutSmart TM Buffer (New England Biolabs (NEB), 
Ipswich, MA) at 37°C for 1 hour, separated by gel electrophoresis and extracted by 
QIAquick Gel Extraction Kit. Digested GOI was inserted into the vector by T4 DNA 
ligase (NEB), incubated at 16°C overnight. After chilled on ice for 10 minutes, the 
mixture was added to 50μl of competent cells (NEB DH5αTM Competent E.coli), gently 
flicked and placed on ice for 30 minutes. After heat shock in a 42°C water bath for 30 s, 
the cells were placed on ice for another 5 minutes. 900 μl of SOC was added and then 
incubated in a incubator shaker at 250 rpm, at 37°C for 1 hour. Subsequently, the cells 
were centrifuged, resuspended in 100 μl of SOC buffer, and then spread on LB agar 
plates containing Ampicillin (50 μg/ml). After incubated at 37°C overnight, individual 
bacterial colonies was picked and amplified in 4ml of LB broth containing ampicillin (50 
μg/ml). Plasmid was extracted from the overnight bacterial culture by QIAprep® Spin 
Miniprep Kit. Correct recombinant plasmids were determined by diagnostic restriction 
digestion and sequencing.  
 
Transposition: The recombinant plasmid was added to 100 μl competent cells (NEB 
DH10BacTM Competent cells). The mixture was gently flicked and placed on ice for 30 
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minutes. After heat shock in a 42°C water bath for 45s, the mixture was place on ice for 
another 5 minutes, added 900 μl of SOC and incubated in a incubator shaker at 225 rpm, 
at 37°C for 5 hours. The cells were then spread on LB agar plates containing kanamycin 
(50 μg/ml), gentamicin (7 μg/ml), tetracycline (10 μg/ml), Bluo-gal (100 μg/ml), and 
IPTG (40 μg/ml). After incubated at 37°C for 48 hours, single white colonies were picked 
and streaked on fresh LB agar plates as above, and incubated at 37°C overnight. The 
confirmed single colony was inoculated into 5ml of LB broth containing kanamycin (50 
μg/ml), gentamicin (7 μg/ml), and tetracycline (10 μg/ml). Recombinant bacmid DNA 
was subsequently extracted from the 24-hour liquid culture by Miniprep Kit.   
 
Transfection：Sf9 insect cells in log phase (1.5-2.5 × 106 cells/ml) were diluted to 8 × 
106 cells/ml in SF-900TMIII insect culture medium and plated 2ml (1.6× 106 cells) into 
each well of a 6-well plate. The cells were allowed to attach for 15 minutes at room 
temperature in the hood. For each bacmid to be transfected, 6 μl of Cellfectin® II 
Reagent (Invitrogen, Carlsbad, CA) and 6μl of bacmid were separately diluted in 100 μl 
medium and then mixed by inverting the tubes 3 times. The medium in the 6-well plate 
was removed and replaced with the DNA-Lipid mixture. After incubated at 27°C for 5 
hours, the mixture was removed and replaced with 2 ml of SF-900TMIII insect culture 
medium containing 100 units/ml penicillin, and 100 μg/ml streptomycin. After incubated 
at 27°C for 72 hours, baculovirus-containing supernatant in passage 1 (P1) was 
transferred to sterile tubes, aliquoted and stored at -80°C. Baculovrius was gradually 
amplified by Passage 2 (P2), Passage 3 (P3) and Passage 4 (P4). P2 was directly made by 
adding 500 μl of P1 stock to 30 ml of SF9 cells in log phase growing in a 50 ml shake 
flask. Expression of the protein was detected by Western blot. After 7 days, the cell 
culture was transferred to 50 ml centrifuge tubes, spun at 6000 g for 20 minutes at 4°C in 
the swinging bucket rotor. Aliquots of the supernatant were frozen at -80°C. To make P3, 
5 ml of P2 supernatant was transferred to 300 ml of SF9 cells in log phase growing in a 
500 ml shake flask. Supernatant was collected by centrifuge after 7 days. Then, 150 ml of 
P3 supernatant was transferred to 1800 ml of sf9 cells in two 2 L shake flasks to make P4. 
Cell culture was collected once reaching a 40%-50% mortality rate (usually after 3 days).  
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Western blot: Protein expression was detected in P1 and P2 supernatant in day 3. Briefly, 
30 μl of the cell culture was transferred to 1.5 ml tubes. Cells were harvested by spinning 
at 3,000 rpm for 5 minutes using the microfuge. The supernatant was transferred to 
another tube for further analysis. Proteins in each sample were separated by SDS-PAGE 
and transferred onto a PVDF membrane (Bio-Rad Laboratories, Hercules, CA). 
Membranes were blocked in PBST containing 5% non-fat milk for 1 hour at room 
temperature, and incubated with appropriate primary antibodies in PBST+2% non-fat 
milk for 3 hours at room temperature. The blots were washed three times for 10 minutes 
each with PBST and then incubated for 1 hour in room temperature with secondary 
antibodies in PBST+2% non-fat milk. After washed sufficiently, AmershamTM ECLTM 
Prime Western Blotting Detection Reagent (GE Healthcare, Boston, MA) was applied on 
the blot. The signal was detected using myECLTM Imager (ThermoFisher, Waltham, MA). 
 
Samples preparation: P4 supernatant in day 3 was collected by spinning at 6000 g for 
20 minutes in two 1L centrifuge bottles, and condensed in a concentrator to about 50-100 
ml at 4°C. The condensed supernatant was filtered by 0.2 μm bottletop filter. Proteins 
were purified by affinity column, followed by gel filtration. 
 
Affinity chromatography: 5 ml HiTrapTM nickel-chelating HP column (GE Healthcare) 
was used for protein with His6 tag. The column was washed with 60 ml of distilled water, 
followed by 40 ml of 0.05 M EDTA, 20 ml of 0.1 M NiCl2, 60 ml of distilled water and 
100 ml of PBS. The prepared protein-containing samples was pumped onto the column at 
5 ml/min, and washed with 50 ml of PBS buffer. Proteins was eluted by elution buffer 
(buffer A1 and buffer B) containing gradient imidazole using AKTA. Fractions was 
detected by coomassie blue staining method. 5 ml HiTrapTM Protein A HP column (GE 
Healthcare) was used for protein with Fc tag. The column was washed with distilled 
water, followed by 20 ml of PB buffer. The prepared protein-containing samples was 
pumped onto the column at 5 ml/min, and washed with 50 ml of PB buffer. Proteins was 
eluted by 1M citric acid (pH=3.5) and immediately neutralized by 1 M Tris-Base (pH=9). 
The purified fractions was detected by coomassie blue staining method.  
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Gel filtration: About 0.5 ml of condensed protein samples was loaded to HiLoad 
Superdex 200 PG column (GE Healthcare) by syringe. Fractions were detected by 
coomassie blue staining method. Fractions containing target protein were collected and 
condensed using Amicon® Ultra centrifugal filters (Merk Millipore, Billerica, MA). The 
concentration of purified protein was measured using NanoDrop. The protein was 
aliquoted and frozen at -80°C for further analysis. 
 
Coomassie blue staining: 20 μl of sample from each fraction was applied to SDS-PAGE 
gels. After electrophoresis at 120 V for 150 minutes, the gel was rinsed with distilled 
water to remove SDS and buffer salts, and then merged in Coomassie Brilliant Blue G-
250 Dye at room temperature. After 10 minutes, the gel was washed by distaining buffer 
3 time for 10 minutes each. Fractions containing target protein was collected and 
condensed to about 500 μl using Amicon® Ultra centrifugal filters (Merk Millipore, 
Billerica, MA).  
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Biochemical Assays  
Dot blot Hybridization Assay: 2 μl of TGEV or 229E truncated spike proteins (50 
μg/ml) were dotted onto a nitrocellulose membrane and dried completely. The blot was 
blocked in PBST containing 5% non-fat milk at room temperature for 1 hour. The blot 
were then washed with PBST, and incubated overnight at 4°C with 50 μg/ml pAPN, 
which had been preincubated alone or with 100uM of APN inhibitors, actinonin (Sigma-
Aldrich, St. Louis, MO) or bestatin (Santa Cruz, Dallas, TX). After washed 3 times for 10 
minutes, the blot was incubated with anti-His6 mouse monoclonal IgG1 antibody (Santa 
Cruz, Dallas, TX) at 37°C for 2 hours, and then incubated with HRP-conjugated goat 
anti-mouse IgG antibody (Santa Cruz, Dallas, TX) at 37°C for 1 hour after washed three 
times with PBST. Finally, the blot was thoroughly washed and detected using ECL Plus 
(GE Healthcare).  
 
ELISA: NuncTM MicroWellTM 96-well Microplates (ThermoFisher, Waltham, MA) were 
coated overnight at 4°C with 100 μg/ml TGEV spike, 5μg/ml MERS-CoV spike or 5 
μg/ml SARS-CoV spike. After blocking at room temperature for 2 hours, the plate were 
incubated at 37°C for 3 hours with 100 μg/ml pAPN, hDPP4 or hACE2. The plate was 
then treated in the same way as dot-blot hybridization assay with primary and HRP-
conjugated secondary antibodies. After washed three times, the plate was incubated with 
TMB substrate (3, 3', 5, 5'- Tetramethylbenzidine) for 10 minutes, and the reaction was 
stopped by 1 M H2SO4. The color reaction was quantified using Tecan Infinite M1000 
PRO Microplate reader at 450 nm. 
 
BLItz: The BLItz (ForteBio, Menlo Park, CA) was used to measure the binding kinetics 
of  CoV spikes with receptors incubated with or without inhibitors at room temperature. 
Purified spikes in PBS were immobilized on protein A biosensors. Biosensor tips were 
equilibrated in PBS before associated with receptors preincubated with PBS or inhibitors 
for 1 hour. Dissociation is then allowed in PBS. The real-time binding process will 
display in each experiment and analyzed by global fitting. 
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Table 7. The steps of advanced kinetics experiment in BLItz 
 
Step Type Duration (seconds) Position 
Initial Baseline 30 Tube (250 μl) 
Loading 120 Drop (4 μl) 
Baseline 300 Tube (250 μl) 
Association 120 Drop (4 μl) 
Dissociation 120 Tube (250 μl) 
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Cell Experiments 
 
Cell lines: The HEK 293T (human embryonic kidney) was obtained from ATCC 
(www.atcc.org). Huh-7 (human liver) was kindly provided by Charles M. Rice at 
Rockefeller University and Chien-Te K. Tseng at the University of Texas Medical 
Branch, respectively. These cell lines were maintained in Dulbecco’s modified Eagle 
medium, supplemented with 10% FBS, 2mM L-glutamine, and 1% 
penicillin/streptomycin (Life Technologies Inc, Grand Island, NY). 
 
Downstream of endogenous APN in Huh-7 by bestatin with gradient concentration: 
Huh-7 cells were preincubated with supplemented DMEM media with 0 μM, 10 μM, or 
100 μM bestatin (DMSO solution) at 37℃ for 24 hours. The media was then removed 
and the cells were washed with PBS once. Lysis buffer was added and incubated at room 
temperature for 30 minutes.  The cell lysates were slightly shaken and further analyzed 
by Western blot. 
 
Downstream of endogenous APN in Huh-7 by inhibitors at different time points: 
Huh-7 cells were preincubated with supplemented DMEM media with 0 or 100 μM 
inhibitor (DMSO solution) at 37℃. The cells were harvested as previously described at 0 
hour, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 24 hours post-treatment and 
analyzed by Western blot.  
 
Western blot: The level of APN expression in cell lysates was detected by Western blot 
as previously described. 
 
Reverse- Transcription PCR (RT-PCR): RNA from each sample was extracted by 
QIAgen® RNeasy Plus Mini Kit. RNA was converted to cDNA using RT-PCR. For each 
sample, 1 μg of RNA were initially incubated at 70°C for 10 minutes and placed on ice. 
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20 μl of the reaction mixture was incubated at 37°C for one hour, then heated to 95°C for 
5 minutes and stored at 4°C for further use.  
 
 
Table 8. Reaction mixture of RT-PCR 
 
Component Volume 
Reverse Transcription 10× buffer 2 μl 
MgCl2 (25 mM) 4 μl 
dNTP mix (2.5 mM each NTP) 8 μl 
AMV Reverse Transcriptase (High Conc.) 0.6 μl 
Oligo (dT) 15 primer (0.5 μg/ul) 1 μl 
RNA (Conc. varies) 1 μg 
Nuclease-Free Water to a final volume  20 μl 
 
Real-Time PCR (RT-PCR): APN transcription level was quantified by RT-PCR in 
StepOnePlus™ Real-Time PCR System (ThermoFisher, Waltham, MA) with SYBR™ 
Green dye (ThermoFisher, Waltham, MA) from Applied biosystems as sequence 
detecting reagent. Amplifications were performed in a 10 μl reaction mixture. The 
reaction an initial denaturation at 95°C, followed by 40 cycles of 15 seconds at 95°C, 15 
seconds at 50°C and 1 minute at 72°C. An extension phase of 15 seconds at 95°C and 
then 1 minute at 60°C was conducted to detect the format of primers annealing. Instant 
fluorescence was measured in each cycle, and the number of target copies in each 
reaction was deduced from the threshold cycle (CT) using Delta Delta CT method. The 
number of GAPDH copies was used as a internal control.   
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Table 9. Primers for RT-PCR 
 
mRNA upstream downstream 
ANPEP (APN) CCTGTCATCAATCGGGC AGTAGCTCAGGCTGCTCAGG  
GAPDH CCATCAATGACCCCTTCATTGACCT TCTCGCTCCTGGAAGATGGT 
 
Inhibition of APN expression by spikes:  HEK 293T cells transiently expressing pAPN  
were incubated with 20 μg/ml of TGEV spike for 24 hours at 37℃. Huh 7 cells were 
incubated with 20 μg/ml of HCoV-229E spike for 24 hours at 37℃. The level of APN 
expression in cell lysates was detected by Western blot as previously described. 
 
Pseudovirus Production: Retroviruses pseudotyped with HCoV-229E spike were 
generated. A plasmid carrying an env-defective, luciferase-expressing HIV, type 1 
genome(pNL4-3.luc.R-E-) and a plasmid encoding HCoV-229E spike were co-
transfected into HEK 293T cells using Lipofectamine 3000 reagent (Invitrogen, Carlsbad, 
CA) according to the instructions of the manufacturer. Supernatants containing 
pseudoviruses were harvested after 72 hours of transfection. Cell debris were removed by 
centrifugation. 
 
Pseudovirus Entry: Retrovirus pseudotyped with HCoV-229E Spike or empty vector 
(mock) were used to transduce Huh 7 cells in 96-well plates. Briefly, cells were 
preincubated with APN inhibitors in supplemented DMEM (ThermoFisher, Waltham, 
MA) for 1 hour. After treatment, cells were infected with the pseudovirus in the presence 
or absence of bestatin (Santa Cruz, Dallas, TX) respectively for 2 hours and subsequently 
replaced with fresh DMEM (ThermoFisher, Waltham, MA) with or without bestatin 
(Santa Cruz, Dallas, TX), 10% FBS, L-glutamine, 100 units/ml of penicillin and 
streptomycin (Invitrogen, Carlsbad, CA). Forty-eight hours later, cells were washed with 
PBS, lysed, and then transferred to an Optiplate-96 plate (PerkinElmer, Waltham, MA). 
After Luciferase substrate (Promega, Madison, WI) was added, relative lucifierase units 
were measured immediately using EnSpire plate reader(PerkinElmer, Waltham, MA).  
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